In summary, our findings not only uncover a novel regulatory approach underlying gemcitabine resistance and aberrant activation of the Akt signaling pathway, but also offer new insight into tailoring the specific combination regimen for patients with pancreatic cancer. The gene discussed is AKT1; the disease is familial pancreatic carcinoma.